Regenxbio Inc. (RGNX) Stock Price & Analysis
Regenxbio Inc. (RGNX) fell 5.07% to USD 9.73 as of July 25, 2026 at 03:44 UTC, according to Nexqual real-time market data.
RGNX last closed at USD 10.25; the session ranged USD 9.58–10.34 on volume of 959,501 shares. Market capitalization is $622.92M, with a 52-week range of USD 5.46–16.19 (NMS). Source: Nexqual, July 25, 2026 at 03:44 UTC.
Key Statistics (as of July 25, 2026 at 03:44 UTC)
| Price | USD 9.73 |
|---|---|
| Change | ▼ 5.07% (down) |
| Previous Close | USD 10.25 |
| Open | USD 10.24 |
| Day Range | USD 9.58 – 10.34 |
| 52-Week Range | USD 5.46 – 16.19 |
| Volume | 959,501 shares |
| Market Cap | $622.92M |
| Exchange | NMS |
Technical Analysis (RGNX)
Nexqual's technical model rates RGNX "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:44 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 44.72 (neutral) |
| vs SMA50 | Above (USD 9.15) |
| MACD | 0.12 (positive) |
Analyst Ratings (RGNX)
Wall Street analysts rate RGNX "Buy" based on 11 analysts, with a mean price target of USD 24.27 (range USD 10–50), per Nexqual as of July 25, 2026 at 03:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 24.27 |
| High Target | USD 50 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (RGNX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $96.46M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.72 vs est -1.41 ▼ miss |
| 2025-12-31 | USD -1.3 vs est -0.84 ▼ miss |
| 2025-09-30 | USD -1.2 vs est -1.3 ▲ beat |
| 2025-06-30 | USD -1.38 vs est -1.05 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financials & Fundamentals (RGNX)
| Total Revenue | $87.82M |
|---|---|
| Revenue Growth (YoY) | -92.80% |
| Gross Margin | -196.61% |
| Operating Margin | -1303.96% |
| Profit Margin | +0.00% |
| ROE | -196.43% |
| Debt / Equity | 1,178.24 |
| Current Ratio | 2.62 |
| Total Cash | $150.49M |
| Total Debt | $248.40M |
| Free Cash Flow | $-138.98M |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financial Health Score (RGNX)
Nexqual rates Regenxbio Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:44 UTC.
| Growth | Strong — Revenue +105% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $150M cash vs $248M debt |
| Cash Flow | Weak — FCF negative: -$139M, burning cash |
| Efficiency | Critical — ROE -196%, ROA -38.5% |
Ownership (RGNX)
| Insider Ownership | +6.59% |
|---|---|
| Institutional Ownership | +66.89% |
| Shares Outstanding | 64.02M |
| Float | 44.45M |
| Short % of Float | +21.77% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Leadership (RGNX)
Regenxbio Inc. is led by Curran M. Simpson M.S. (age 63), President, CEO & Director, per Nexqual as of July 25, 2026 at 03:44 UTC.
| President, CEO & Director | Curran M. Simpson M.S. (age 63) |
|---|---|
| Executive VP & Chief Strategy and Legal Officer | Patrick J. Christmas II (age 54) |
| Executive VP & CFO | Mitchell Chan (age 44) |
| Executive VP of Product Development & CTO | Craig Malzahn (age 52) |
| Executive VP & Chief Scientific Officer | Olivier Danos (age 67) |
Major Backers & Investors (RGNX)
Notable institutional backers of Regenxbio Inc. include JPMorgan, Redmile Group, LLC, Morgan Stanley, according to Nexqual as of July 25, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 10.13% |
| Redmile Group, LLC | 8.45% |
| Morgan Stanley | 4% |
| Goldman Sachs | 3.56% |
| Integral Health Asset Management, LLC | 2.9% |
| Qube Research & Technologies Ltd | 2.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 14.16% |
| State Street | 9.06% |
| Vanguard Group | 8.4% |
| Geode Capital | 2.2% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
From Regenxbio Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
- Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
- The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.
- It also develops RGX-111 for the treatment of mucopolysaccharidosis type I.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VYGR | Voyager Therapeutics, Inc. | USD 3.1 | ▲ 0% |
| QURE | uniQure N.V. | USD 38.97 | ▼ 3.49% |
| MGTX | MeiraGTx Holdings plc | USD 11.77 | ▼ 3.21% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 26.9 | ▼ 2.69% |
| XNCR | Xencor, Inc. | USD 19.44 | ▼ 0.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:44 UTC. This page is informational and not investment advice.